This program provides an interdisciplinary curriculum designed to enhance the management of Amyloid-Related Imaging Abnormalities (ARIA) among key specialties, including neurology, psychiatry, radiology, emergency medicine, and primary care. As novel anti-amyloid beta monoclonal antibodies like lecanemab and donanemab gain FDA approval, understanding ARIA's adverse effects becomes increasingly critical. The program emphasizes teamwork, communication, and tailored education to address the persistent challenges in ARIA recognition and management, ultimately aiming to optimize Alzheimer’s treatment. Through diverse, interactive educational activities, clinicians will improve their diagnostic and management skills, ensuring comprehensive and effective patient care.
